Our response to UK health regulator’s rejection of lecanemab as treatment for Alzheimer’s disease
UK medicines regulator MHRA has approved the new Alzheimer’s drug, lecanemab, for use in the UK. However, an interim decision by NICE has deemed lecanemab not cost-effective for the NHS.